DocMorris shares declined 3.2% to 9.32 Swiss francs in early trading on Wednesday, erasing gains despite a strong first-half 2026 performance and upgraded annual guidance. The online pharmacy reported a 38% increase in prescription drug (Rx) sales and a 71% jump in digital services revenue, yet the market response remained negative.
The Zurich Cantonal Bank (ZKB) maintained a 'Hold' rating on DocMorris, citing balanced growth and cost efficiency as critical factors. The bank noted that planned AI-driven workforce reductions, targeting 7% of full-time roles, could mitigate operational pressures. However, the company faces structural challenges, including a 2027 refinancing requirement and negative free cash flow and operating results.
DocMorris aims to reduce these risks by achieving positive free cash flow and strengthening equity through a pending 50 million Swiss franc convertible bond. ZKB’s outlook aligns with a cautious market consensus: five analysts rate the stock a 'Buy,' four maintain 'Hold,' and none recommend selling. The average price target stands at 11.54 Swiss francs, implying a 20% upside potential.
The decline in DocMorris shares reflects two key factors. First, the 'sell the news' phenomenon, as the company’s mid-July trading update had already priced in strong prescription growth. Second, competitive pressure from Redcare, whose German prescription revenue surged 58%—outpacing DocMorris’s 38% gain. Investors now face the risk of further market share erosion, contributing to the negative sentiment.
ZKB’s revised ratings—improved from four 'Buy,' four 'Hold,' and one 'Sell' six months ago—suggest growing confidence in the stock’s long-term prospects, despite near-term headwinds.
